Cytomx Thera (CTMX) Stock Price, Quote & News

Latest News on CTMX

Jan 6, 2025, 4:05 PM EST - 12 days ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 2 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 2 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 4 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 5 months ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 7 months ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 7 months ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 22, 2024, 4:05 PM EDT - 8 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 16, 2024, 4:15 PM EDT - 8 months ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 9 months ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 9 months ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 9 months ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 9 months ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 9 months ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 9 months ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 18, 2024, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 11, 2024, 6:39 PM EDT - 11 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:10 PM EDT - 11 months ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 4, 2024, 8:00 AM EST - 11 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Feb 27, 2024, 8:00 AM EST - 11 months ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Dec 21, 2023, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 2:32 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Oct 31, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

Oct 18, 2023, 4:30 PM EDT - 1 year ago

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

Sep 5, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 10, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 8, 2023, 10:57 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

Jul 17, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

Jun 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

Jun 1, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 11:13 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 4:01 PM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

Apr 25, 2023, 4:05 PM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Mar 27, 2023, 7:51 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

Mar 27, 2023, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Mar 22, 2023, 7:23 PM EDT - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

Jan 26, 2023, 7:00 AM EST - 2 years ago

Market Cap	65.74M
Revenue (ttm)	101.21M
Net Income (ttm)	-570,000.00
EPS (ttm)	N/A
PE Ratio	4.98
Forward PE	N/A
Profit Margin	-0.56%
Debt to Equity Ratio	0.00

Volume	621,100
Avg Vol	1,404,566
Day's Range	N/A - N/A
Shares Out	78.26M
Stochastic %K	13%
Beta	1.03
Analysts	Strong Sell
Price Target	$4.96